RxDoctor Payments Data

Paul Yates, MD

Ophthalmology · Charlottesville, VANPI 1508833997

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Sight Sciences, Inc.. That places this record below the midpoint for ophthalmology clinicians in VA, where the typical reported total is $1,018.

$39in general payments, 2019–2025

Across 1 payment — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$39
$294,672in research payments, 2019–2025

Across 31 payments — averaging $9505.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$175K
  • Apellis Pharmaceuticals, Inc.$120K

What the payments were for

  • Food & beverage$39100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sight Sciences, Inc.1$39

How this compares

$39 in reported general payments places this provider in the 5th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$238,447
Medicare patients
699
Services billed
4,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate35$879
Ketorolac Tromethamine15$243
Latanoprost14$177
ErythromycinErythromycin Base13$148

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →